Mitesh Borad, M.D., an oncologist at Mayo Clinic in Arizona, was part of the research for a new drug proven to give pancreatic cancer patients more time. He speaks on pancreatic cancer, risk factors a
· 1 min readNews
Source
Twitter / XMitesh Borad, M.D., an oncologist at Mayo Clinic in Arizona, was part of the research for a new drug proven to give pancreatic cancer patients more time. He speaks on pancreatic cancer, risk factors aconsent.youtube.comMitesh Borad, M.D., an oncologist at Mayo Clinic in Arizona, was part of the research for a new drug proven to give pancreatic cancer patients more time. He speaks on pancreatic cancer, risk factors and what’s on the horizon for treatment and research
You might also wanna read
Experimental pill daraxonrasib extends survival in advanced pancreatic cancer patients, study finds
Researchers reported that daraxonrasib, a novel experimental pill, helped patients with advanced pancreatic cancer live longer by blocking a
npr.org·29d agoNew AI Tool Boosts Pancreatic Cancer Detection – Asian Scientist Magazine
asianscientist.com
Spanish Researchers Develop Breakthrough Therapy Protocol for Pancreatic Cancer Treatment
Spanish researchers have developed a new therapy protocol that could revolutionize pancreatic cancer treatment. Pancreatic cancer is notorio
nypost.com·4mo agoDaraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer | NEJM
nejm.org·29d ago
Experimental pill daraxonrasib nearly doubles survival time in advanced pancreatic cancer patients
A novel experimental pill called daraxonrasib has shown promise in extending survival for patients with advanced pancreatic cancer. The drug
chicagotribune.com·1mo ago
Experimental daraxonrasib pill extends survival for advanced pancreatic cancer patients, study finds
An experimental pill called daraxonrasib has shown promise in helping patients with advanced pancreatic cancer live longer. The drug blocks
bit.ly·1mo ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.